<DOC>
	<DOCNO>NCT00036296</DOCNO>
	<brief_summary>The purpose research study test safety effectiveness study drug , Talampanel , use treat patient involuntary movement know dyskinesia , result treatment Parkinson 's disease . It clear people Parkinson 's disease develop involuntary movement ( dyskinesia ) study show block receptor brain chemical call glutamate decrease movement . Talampanel drug block receptor .</brief_summary>
	<brief_title>Effects Talampanel Patients With Advanced Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>Troublesome onperiod dyskinesias define Unified Parkinson 's Disease Rating Scale ( UPDRS ) dyskinesia subscore &gt; 25 % Duration dyskinesia waking hour 33 must moderate disability LangFahn dyskinesia rating score 2 least two 5 task Must Dyskinesia average 25 % wake hours/day base Patient Diaries Have diagnose Parkinson 's disease &gt; 5 year Screening Previous surgical therapy PD Isolated predominantly diphasic dyskinesia Moderate Dementia On disallow concomitant medication include CYP3A4 inhibitor inducer , amantadine , etc .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Involuntary Movements</keyword>
	<keyword>Abnormal Movements</keyword>
	<keyword>Advanced Parkinson 's disease</keyword>
	<keyword>Levodopa induce dyskinesia</keyword>
</DOC>